99-3146. Notice of Filing of Pesticide Petitions  

  • [Federal Register Volume 64, Number 26 (Tuesday, February 9, 1999)]
    [Notices]
    [Pages 6351-6357]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 99-3146]
    
    
    =======================================================================
    -----------------------------------------------------------------------
    
    ENVIRONMENTAL PROTECTION AGENCY
    
    [PF-856; FRL-6058-3]
    
    
    Notice of Filing of Pesticide Petitions
    
    AGENCY: Environmental Protection Agency (EPA).
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
    SUMMARY: This notice announces the initial filing of pesticide 
    petitions proposing the establishment of regulations for residues of 
    certain pesticide chemicals in or on various food commodities.
    
    DATES: Comments, identified by the docket control number PF-856, must 
    be received on or before March 11, 1999.
    
    ADDRESSES: By mail submit written comments to: Public Information and 
    Records Integrity Branch, Information Resources and Services Division 
    (7502C), Office of Pesticides Programs, Environmental Protection 
    Agency, 401 M St., SW., Washington, DC 20460. In person bring comments 
    to: Rm. 119, CM #2, 1921 Jefferson Davis Highway, Arlington, VA.
        Comments and data may also be submitted electronically to: docket@epamail.epa.gov. Follow the instructions under ``SUPPLEMENTARY 
    INFORMATION.'' No confidential business information should be submitted 
    through e-mail.
        Information submitted as a comment concerning this document may be 
    claimed confidential by marking any part or all of that information as 
    ``Confidential Business Information'' (CBI). CBI should not be 
    submitted through e-mail. Information marked as CBI will not be 
    disclosed except in accordance with procedures set forth in 40 CFR part 
    2. A copy of the comment that does not contain CBI must be submitted 
    for inclusion in the public record. Information not marked confidential 
    may be disclosed publicly by EPA without prior notice. All written 
    comments will be available for public inspection in Rm. 1132 at the 
    address given above, from 8:30 a.m. to 4 p.m., Monday through Friday, 
    excluding legal holidays.
    
    FOR FURTHER INFORMATION CONTACT: The product manager listed in the 
    table below:
    
    ------------------------------------------------------------------------
                                       Office location/
            Product Manager            telephone number          Address
    ------------------------------------------------------------------------
    Joanne I. Miller (PM 23)......  Rm. 237, CM #2, 703-    1921 Jefferson
                                     305-6224, e-            Davis Hwy,
                                     mail:[email protected]   Arlington, VA
                                     amail.epa.gov.
    Sidney Jackson (PM 23)........  Rm. 233, CM #2, 703-    Do.
                                     305-7610, e-mail:
                                     jackson.sidney@epamai.
    ------------------------------------------------------------------------
    
    SUPPLEMENTARY INFORMATION: EPA has received pesticide petitions as 
    follows proposing the establishment and/or amendment of regulations for 
    residues of certain pesticide chemicals in or on various food 
    commodities under section 408 of the Federal Food, Drug, and Comestic 
    Act (FFDCA), 21 U.S.C. 346a. EPA has determined that these petitions 
    contain data or information regarding the elements set forth in section 
    408(d)(2); however, EPA has not fully evaluated the sufficiency of the 
    submitted data at this time or whether the data supports granting of 
    the petition. Additional data may be needed before EPA rules on the 
    petition.
        The official record for this notice of filing, as well as the 
    public version, has been established for this notice of filing under 
    docket control number [PF-856] (including comments and data submitted 
    electronically as described below). A public version of this record, 
    including printed, paper versions of electronic comments, which does 
    not include any information claimed as CBI, is available for inspection 
    from 8:30 a.m. to 4 p.m., Monday through Friday, excluding legal 
    holidays. The official record is located at the address in 
    ``ADDRESSES'' at the beginning of this document.
        Electronic comments can be sent directly to EPA at:
        opp-docket@epamail.epa.gov
    
    
        Electronic comments must be submitted as an ASCII file avoiding the 
    use of special characters and any form of encryption. Comments and data 
    will also be accepted on disks in Wordperfect 5.1 file format or ASCII 
    file format. All comments and data in electronic form must be 
    identified by the docket number (insert docket number) and appropriate 
    petition number. Electronic comments on notice may be filed online at 
    many Federal Depository Libraries.
    
    List of Subjects
    
        Environmental protection, Agricultural commodities, Food additives, 
    Feed additives, Pesticides and pests, Reporting and recordkeeping 
    requirements.
    
        Dated: January 29, 1999.
    
    James Jones,
    
    Director, Registration Division, Office of Pesticide Programs.
    
    Summaries of Petitions
    
        Petitioner summaries of the pesticide petitions are printed below 
    as required by section 408(d)(3) of the FFDCA. The summaries of the 
    petitions were prepared by the petitioners and represent the views of 
    the petitioners. EPA is publishing the petition summaries verbatim 
    without editing them in any way. The petition summary announces the 
    availability of a description of the analytical methods available to 
    EPA for the detection and measurement of the pesticide chemical 
    residues or an explanation of why no such method is needed.
    
    1. Dow AgroSciences LLC
    
     PP 8F 3600
    
        EPA has received a pesticide petition (8F 3600) from Dow 
    AgroSciences LLC, 9330 Zionsville Road, Indianapolis, IN 46268, 
    proposing pursuant to section 408(d) of the Federal Food, Drug, and 
    Cosmetic Act (FFDCA), 21 U.S.C. 346a(d), to amend 40 CFR part 180 by 
    establishing a tolerance for residues of the herbicide clopyralid in or 
    on the raw agricultural commodity sugar beet, roots at 2.0 parts per 
    million (ppm) and sugar beet, tops at 3.0 ppm and on the processed 
    agricultural commodity (PAC) sugar beet, molasses at 16.0 ppm. at sugar 
    beet, roots at 2.0 ppm and sugar beet, tops at 3.0 ppm and on the 
    processed agricultural commodity (PAC) sugar beet, molasses at 16.0 
    ppm. EPA has determined that the petition contains data or information 
    regarding the elements set forth in section 408(d)(2) of the FFDCA; 
    however, EPA has not fully evaluated the sufficiency
    
    [[Page 6352]]
    
    of the submitted data at this time or whether the data supports 
    granting of the petition. Additional data may be needed before EPA 
    rules on the petition.
    
    A. Residue Chemistry
    
        1. Plant metabolism. The metabolism in plants is adequately 
    understood. No metabolites of significance were detected in plant 
    metabolism studies.
        2. Analytical method. There is a practical analytical method for 
    detecting and measuring levels of clopyralid in or on food with a limit 
    of quantitation (LOQ) of 0.05 ppm that allows monitoring of food with 
    residues at or above the levels set in these tolerances. EPA has 
    provided information on this method to FDA. The method is available to 
    anyone who is interested in pesticide residue enforcement.
        3. Magnitude of residues. Tolerances for residues of the herbicide 
    clopyralid in or on the following raw agricultural commodities, sugar 
    beet roots and tops and the processed agricultural commodity molasses, 
    were established on August 12, 1988 (53 FR 33488, 33489) at 0.5, 0.5, 
    and 7.0 ppm, respectively, based upon residue data generated by Craven 
    Laboratories. The validity of these data were in question and Dow 
    AgroSciences repeated the residue studies. The last of the required 
    residue data using a 105 day pre-harvest interval (PHI) were submitted 
    to the Agency in June 1994. This pesticide petition proposes increased 
    tolerances based upon data using a 45 day PHI. Residues of clopyralid 
    were determined in roots and tops from several varieties of sugar 
    beets, which were harvested from plots treated at the currently labeled 
    season-maximum rate of 0.25 lb ae/acre in one application. Field test 
    plots were located at thirteen sites representing the major U.S. 
    production areas. Highest residues at the 45 day PHI for roots averaged 
    0.91 g/g with the highest individual value of 1.47 g/
    g, and for tops averaged 1.52 g/g with the highest individual 
    value of 2.48 g/g. Based on the data, it is expected that 
    residues of clopyralid in or on sugar beets as a raw agricultural 
    commodity will not exceed proposed revised tolerances of 2 g/g 
    in roots and 3 g/g in tops when the PHI is 45 days or longer. 
    With a concentration factor of 8, the proposed tolerance for sugar beet 
    molasses is 16 g/g. The proposed revised tolerances would 
    adequately cover these anticipated residues.
    
    B. Toxicological Profile
    
        1. Acute toxicity. Clopyralid has low acute toxicity. The rat oral 
    LD50 is 5,000 milligram/kilograms (mg/kg) or greater for 
    males, and females. The rabbit dermal LD50 is greater than 
    2,000 mg/kg and the rat inhalation LC50 is greater than 1.0 
    mg/L air (the highest attainable concentration). In addition, 
    clopyralid is not a skin sensitizer in guinea pigs and is not a dermal 
    irritant. Technical clopyralid is an ocular irritant but ocular 
    exposure to the technical material would not normally be expected to 
    occur to infants or children or the general public. End use 
    formulations of clopyralid have similar low acute toxicity profiles and 
    most have low ocular toxicity as well. Therefore, based on the 
    available acute toxicity data, clopyralid does not pose any acute 
    dietary risks.
        2. Genotoxicty. Clopyralid is not genotoxic. The following studies 
    have been conducted and all were negative for genotoxic responses. Ames 
    bacterial mutagenicity assay (with and without exogenous metabolic 
    activation); Host-Mediated assay In vivo cytogenetic test, rat; In vivo 
    cytogenetic test, mouse; In vivo dominant lethal test, rat; In vitro 
    unscheduled DNA synthesis assay in primary rat hepatocyte cultures; In 
    vitro mammalian cell gene mutations assay in Chinese hamster ovary cell 
    cultures (with and without exogenous metabolic activation).
        3. Reproductive and developmental toxicity. Developmental toxicity 
    was studied using rats and rabbits. The developmental study in rats 
    resulted in a developmental no-observed adverse effect level (NOAEL) of 
    > 250 milligram/kilograms/day (mg/kg/day) (a maternally toxic dose) and 
    a maternal toxicity NOAEL of 75 mg/kg/day. A 1974 study in rabbits 
    revealed no evidence of developmental or maternal toxicity at 250 mg/
    kg/day; thus the developmental and maternal NOAEL was > 250 mg/kg/day. 
    A more recent study in rabbits (1990) resulted in developmental and 
    maternal NOAELs of 110 mg/kg/day based on maternal toxicity at 250 mg/
    kg/day. Based on all of the data for clopyralid, there is no evidence 
    of developmental toxicity at dose levels that do not result in maternal 
    toxicity. In a 2-generation reproduction study in rats, pups from the 
    high dose group which were fed diets containing clopyralid had a slight 
    reduction in body weight during lactation and an increase in liver 
    weights in F1a and F1b weanlings. The NOAEL for parental systemic 
    toxicity was 500 mg/kg/day. There was no effect on reproductive 
    parameters at > 1,500 mg/kg/day nor was there an adverse effect on the 
    morphology, growth or viability of the offspring; thus, the 
    reproductive NOAEL is > 1,500 mg/kg/day.
        4. Subchronic toxicity. The following studies have been conducted 
    using clopyralid. In a rat 90 day feeding study, Fischer 344 rats were 
    fed diets containing clopyralid at doses of 5, 15, 50 or 150 mg/kg/day 
    with no adverse effects attributed to treatment. In a second study, 
    Fischer 344 rats were fed diets containing clopyralid at doses of 300, 
    1,500 and 2,500 mg/kg/day. Effects at the highest doses were decreased 
    food consumption accompanied by decreased body weights and weight gains 
    in both males and females. Slightly increased mean relative liver and 
    kidney weights were noted in males of all doses, and in females at the 
    top 2 doses. Because there were no other effects, the kidney and liver 
    weight effects were judged as being adaptive rather than directly 
    toxic. The no-observed adverse effect level (NOAEL) was 1,500 mg/kg/day 
    for males and females. The NOAEL was 300 mg/kg/day for females. In a 
    mouse 90 day feeding study, B6C3F1 mice were fed diets containing 
    clopyralid at doses of 200, 750, 2,000 or 5,000 mg/kg/day. A slight 
    decrease in body weight occurred at the top dose in both sexes. The 
    liver was identified as the target organ based on slight increases in 
    liver weights and minimal microscopic alterations at the higher dose 
    levels. The liver changes were considered to be reversible and 
    adaptive. The NOAEL for males was 2,000 mg/kg/day, and for females was 
    750 mg/kg/day. In a 180 day feeding study, beagle dogs were fed diets 
    containing clopyralid at doses of 15, 50 or 150 mg/kg/day; there were 
    no adverse effects. In a second dietary study, dogs also were fed diets 
    containing clopyralid at doses of 15, 50 or 150 mg/kg/day; the only 
    effect was an increase in the mean relative liver weight in females at 
    the 150 mg/kg/day. In a 21 day dermal study, clopyralid was applied by 
    repeated dermal application to New Zealand White rabbits at dose levels 
    up to 1,000 mg/kg/day. Treatment produced no systemic effects.
        5. Chronic toxicity. In a chronic toxicity and oncogenicity study, 
    Sprague-Dawley rats were fed diets containing clopyralid at doses of 5, 
    15, 50 or 150 mg/kg/day. The only effect was a trend toward a decreased 
    body weight of female rats receiving the 150 mg/kg/day dose with a 
    NOAEL of 50 mg/kg/day. In a second study clopyralid was fed to Fischer 
    344 rats in the diet at doses of 15, 150 or 1,500 mg/kg/day. The 
    effects were confined almost entirely to the 1,500 mg/kg/day dose 
    groups and included slightly decreased food consumption and body 
    weights, slightly increased liver and kidney
    
    [[Page 6353]]
    
    weights and macroscopic and microscopic changes in the stomach. No 
    tumorigenic response was present. The NOAEL for this study was 150 mg/
    kg/day. B6C3F1 mice were maintained for 2 years on diets formulated to 
    provide targeted dose levels of 10, 500 or 2,000 mg/kg/day. The only 
    evidence of toxicity was body weight depression in males dosed at 2,000 
    mg/kg/day. There was no evidence of tumorigenic response at any dose 
    level. Based on the chronic toxicity data, EPA has established the RfD 
    for clopyralid at 0.5 mg/kg/day. The RfD for clopyralid is based on a 2 
    year chronic oncogenicity study in rats with a no-observed-effect level 
    (NOAEL) of 50 mg/kg/day and an uncertainty (or safety) factor of 100. 
    Thus, it would not be necessary to require the application of an 
    additional uncertainty factor above the 100-fold factor already applied 
    to the NOAEL. Using its Guidelines for Carcinogen Risk Assessment 
    published September 24, 1986 (51 FR 33992), clopyralid would be 
    classified as Group E for carcinogenicity (no evidence of 
    carcinogenicity) based on the results of the carcinogenicity studies. 
    There was no evidence of carcinogenicity in 2 year feeding studies in 
    mice and rats at the dosage levels tested. The doses tested are 
    adequate for identifying a cancer risk. Thus, a cancer risk assessment 
    would not be appropriate.
        6. Animal metabolism. Disposition and metabolism of clopyralid were 
    tested in male and female rats at a dose of 5 mg/kg (oral). The 
    majority of a radioactive dose was excreted in 24 hours of all dose 
    groups. Fecal elimination was minor. Detectable levels of residual 
    radioactivity were observed in the carcass and stomach at 72 hours 
    post-dose. HPLC and TLC analysis of urine and fecal extracts showed no 
    apparent metabolism of clopyralid.
        7. Metabolite toxicology. There are no clopyralid metabolites of 
    toxicological significance.
        8. Endocrine disruption. There is no evidence to suggest that 
    clopyralid is neurotoxic.
    
    C. Aggregate Exposure
    
        1. Dietary exposure. For purposes of assessing the potential 
    dietary exposure under these tolerances, exposure is estimated based on 
    the theoretical maximum residue contribution (TMRC) from the existing 
    and this proposed amended tolerance for clopyralid on food crops. The 
    TMRC is obtained by multiplying the tolerance level residues by the 
    consumption data which estimates the amount of those food products 
    eaten by various population subgroups. Exposure of humans to residues 
    could also result if such residues are transferred to meat, milk, 
    poultry or eggs. The following assumptions were used in conducting this 
    exposure assessment. 100% of the crops were treated, the raw 
    agricultural commodities (RAC) residues would be at the level of the 
    tolerance, certain processed food residues would be at anticipated 
    (average) levels based on processing studies and all current and 
    pending tolerances were included. This results in an over estimate of 
    human exposure and a conservative assessment of risk. Based on a NOAEL 
    of 50 mg/kg/day in a 2 year chronic feeding/oncogenicity study in the 
    rat and a hundredfold safety factor, the RfD would be 0.5 mg/kg/day. 
    Consequently, these tolerances have a TMRC of 0.010277 mg/kg/day and 
    would utilize approximately 2.1% of the RfD for the general U.S. 
    population.
        i. Food. The Toxicology database indicates there is no concern 
    regarding acute and chronic dietary risk since the available data do 
    not indicate any evidence of significant toxicity from exposure by the 
    oral route.
        ii. Drinking water. Another potential source of dietary exposure to 
    residues of pesticides are residues in drinking water. There is no 
    established maximum concentration level (MCL) for residues of 
    clopyralid in drinking water. Although there has been limited 
    detections at parts per billion (ppb) levels in some of the specially 
    designed studies under highly vulnerable test conditions, no ongoing 
    monitoring studies (U.S. Geological Survey, Selected Water Resources 
    Abstracts; Pesticides in Ground WaterDatabase - A Compilation of 
    Monitoring Studies: 1971-1991 National Summary; U.S. Department of 
    Agriculture, AGRICOLA database; and, U.S. Department of Commerce, 
    National Technical Information Service) have reported residues of 
    clopyralid in ground or surface waters.
        Based on the physical and chemical characteristics of clopyralid, 
    such as water solubility and its stability under hydrolysis and 
    photolysis, it has potential for downward movement through the soil 
    profile. However, the behavior of the compound under field conditions 
    demonstrates fairly rapid degradation and limited downward movement. 
    Degradation based on 20 field dissipation sites indicated an average 
    half-life of 25 days. Degradation is driven primarily by microbial 
    processes. Downward movement through the soil profile was generally 
    confined to the upper 18 inches of the soil profile. Validated computer 
    modeling also predicted the maximum depth of residues to be 18-inches, 
    with no detections predicted at 6 months after application.
        Because the laboratory derived physical/chemical properties of 
    clopyralid indicate a potential for downward movement, lysimeter 
    studies were conducted. In a U.S. study, undisturbed soil columns 
    (lysimeters), 8 inches in diameter, and 3 feet deep, were treated with 
    950 g ae/ha (about 5 x labeled use rates) in actual field conditions. 
    Residues of clopyralid in soil as well as soil-solution (leachate) were 
    collected in the closed system. The average depth of movement for the 
    majority of clopyralid (center of mass) was 11 inches, and no 
    detectable residues were observed in the leachate. In a European study, 
    lysimeters 1-3 ft. diameter, and 3 ft. deep, were treated with 120 and 
    240 g ae/ha in actual field conditions. The average center of mass was 
    12 inches. No detectable residues were observed in the lysimeters. The 
    amount of 14C in leachate accumulated over 2 years in the 
    degraded loess and silty sand lysimeters, was only 0.6% and 0.3% of 
    applied, respectively. The leachate concentrations of 14C-
    labeled clopyralid in degraded loess and silty sand throughout the 
    first 10-16 months of the study ranged from 0.002-0.14 g/l ppb 
    and 0.003-0.02 ppb, respectively. A second European lysimeter study 
    with silty sand lysimeters treated with 120 g ae/ha revealed a 2 year 
    cumulative clopyralid leachate of only 0.1% of applied (0.04 ppb). 
    These studies demonstrate that in lysimeter test systems, under field 
    environmental conditions, clopyralid rapidly dissipates through 
    mineralization to carbon dioxide. Also the very low levels observed in 
    leachate demonstrate that there is very little potential for clopyralid 
    to leach through soil and contaminate ground water.
        In summary, these data on potential water exposure indicate 
    insignificant additional dietary intake of clopyralid and any exposure 
    is more than compensated for in the conservative dietary risk 
    evaluation. Therefore, it is concluded that there is a reasonable 
    certainty of no harm even at potential upper limit exposures to 
    clopyralid from drinking water.
        2. Non-dietary exposure. There is a non-dietary use registered 
    under the Federal Insecticide, Fungicide and Rodenticide Act. The use 
    is for weed control in residential turf and ornamentals. Potential 
    exposures for children from non-occupational uses is therefore limited 
    to turf and ornamental re-entry and this exposure is low.
    
    [[Page 6354]]
    
        3. Short-term or intermediate-term. The data for clopyralid does 
    not indicate any evidence of significant toxicity by the dermal and 
    inhalation routes. Consequently, there is no concern for short-term or 
    intermediate-term residential risk. Therefore, a short-term or 
    intermediate-term residential risk assessment would not be required.
        4. Chronic. As part of a hazard assessment process an endpoint of 
    concern is determined for the chronic occupational or residential risk 
    assessment. However, as indicated, the exposures that would result from 
    the use of clopyralid are of an intermittent nature. The frequency and 
    duration of these exposures do not exhibit a chronic exposure pattern. 
    The exposure does not occur often enough to be considered a chronic 
    exposure; i.e., a continuous exposure that occurs for at least several 
    months. Therefore, it would not be appropriate to aggregate exposure 
    from the residential use with exposure from food and drinking water.
        5. Acute. No concern would exist for an acute dietary assessment 
    for clopyralid because the available data indicates no evidence of 
    significant toxicity from a 1 day or single event exposure by the oral 
    route. Therefore, an acute dietary risk assessment would not be 
    required.
    
    D. Cumulative Effects
    
        The potential for cumulative effects of clopyralid and other 
    substances that have a common mechanism of toxicity was considered. The 
    mammalian toxicity of clopyralid is well defined. However, no reliable 
    information exists to indicate that toxic effects produced by 
    clopyralid would be cumulative with those of any other chemical 
    compound. Additionally, clopyralid does not appear to produce a toxic 
    metabolite produced by other substances. Therefore, consideration of a 
    common mechanism of toxicity with other compounds is not appropriate at 
    this time. Thus, only the potential exposures to clopyralid were 
    considered in the aggregate exposure assessment.
    
    E. Safety Determination
    
        1. U.S. population. Based on a NOAEL of 50.80 milligram/kilogram/ 
    body weight/day (mg/kg/bwt/day) from a 2 year rat feeding study with a 
    decreased mean bwt gain effect, and using an uncertainty factor of 100 
    to account for the interspecies extrapolation and intraspecies 
    variability, a RfD of 0.5 mg/kg/bwt/day was used for this assessment of 
    chronic risk. As indicated, there is no endpoint of concern identified 
    with acute and short- or intermediate-term exposures. Based on the 
    known toxicity and exposure data, the proposed and existing tolerances 
    would utilize approximately 2.1% of the RfD for the U.S. population. 
    And, as indicated previously, whatever upper limit might be used for 
    drinking water exposure, the exposure estimate for clopyralid would not 
    exceed the RfD. Generally, exposures below 100% of the RfD are of no 
    concern because the RfD represents the level at or below which daily 
    aggregate dietary exposure over a lifetime will not pose appreciable 
    risk to human health. Thus, there is a reasonable certainty that no 
    harm will result from aggregate exposure to clopyralid residues.
        2. Infants and children. In assessing the potential for additional 
    sensitivity of infants and children to residues of clopyralid, data 
    from developmental toxicity studies in the rat and rabbit and a 2-
    generation reproduction study in the rat were considered. The 
    developmental toxicity studies are designed to evaluate adverse effects 
    on the developing organism during prenatal development resulting from 
    pesticide exposure to one or both parents. Reproduction studies provide 
    (i) information relating to effects from exposure to the pesticide on 
    the reproductive capability of mating animals and (ii) data on systemic 
    toxicity.
        Developmental toxicity was studied using rats and rabbits. The 
    developmental study in rats resulted in a developmental NOAEL of > 250 
    mg/kg/day (a maternally toxic dose), and a maternal toxicity NOAEL of 
    75 mg/kg/day. A 1974 study in rabbits revealed no evidence of 
    developmental or maternal toxicity at 250 mg/kg/day; thus the 
    developmental andmaternal NOAEL was > 250 mg/kg/day. A more recent 
    study in rabbits (1990) resulted in developmental and maternal NOAEL's 
    of 110 mg/kg/day based on severe maternal toxicity at 250 mg/kg/day. 
    Based on all of the data for clopyralid, there is no evidence of 
    developmental toxicity at dose levels that do not result in maternal 
    toxicity.
        In a 2-generation reproduction study in rats, pups from the high 
    dose group which were fed diets containing clopyralid had a slight 
    reduction in bwt during lactation and an increase in liver weights in 
    F1a and F1b weanlings. The NOAEL for parental systemic toxicity was 500 
    mg/kg/day. There was no effect on reproductive parameters at > 1,500 
    mg/kg/day nor was there an adverse effect on the morphology, growth or 
    viability of the offspring; thus, the reproductive NOAEL is > 1,500 mg/
    kg/day.
        FFDCA section 408 provides that EPA may apply an additional safety 
    factor for infants and children in the case of threshold effects to 
    account for pre- and post-natal toxicity and the completeness of the 
    database. Based on the current toxicological data requirements, the 
    database relative to pre- and post-natal effects for children is 
    complete. These data suggest minimal concern for developmental or 
    reproductive toxicity and do not indicate any increased pre- or post-
    natal sensitivity. Therefore, an additional uncertainty factor is not 
    necessary to protect the safety of infants and children and that the 
    RfD at 0.5 mg/kg/day is appropriate for assessing aggregate risk to 
    infants and children.
        The percent of the RfD that will be utilized by the aggregate 
    exposure from all tolerances to clopyralid will be much less than 10% 
    for non-nursing infants and for children (1-6 years of age). Therefore, 
    based on the completeness and reliability of the toxicity data and the 
    conservative exposure assessment, it is concluded that there is a 
    reasonable certainty that no harm will result to infants and children 
    from aggregate exposure to clopyralid residues.
    
    F. International Tolerances
    
        There are no Codex maximum residue levels established for 
    clopyralid.
    
    2. IR4 Project
    
     PP 8E4983, 8E5019, 8E5020,8E5021, and 8E5024
    
        EPA has received pesticide petitions (PP 8E4983, 8E5018, 8E5019, 
    8E5020, 8E5021, and 8E5024) from the Interregional Research Project 
    Number 4 (IR-4), proposing pursuant to section 408(d) of the Federal 
    Food, Drug, and Cosmetic Act, 21 U.S.C. 346a(d), to amend 40 CFR part 
    180 by establishing tolerances for residues of the insecticide, 
    tebufenozide (benzoic acid, 3,5-dimethyl-, 1-(1,1-dimethylethyl)-2-(4-
    ethylbenzoyl)hydrazide) in or on the raw agricultural commodities.
        1. PP 8E4983 proposed the establishment of a tolerance for 
    blueberries at 2.0 parts per million (ppm), and PP 8E5018 proposed a 
    tolerance for caneberries at 1.0 ppm. Subsequently, IR-4 amended these 
    tolerance proposals to include a single tolerance at 3.0 ppm for 
    berries (Crop Group 13) that will include both blueberries, and 
    caneberries under PP 8E4983.
        2. PP 8E5024 proposes the establishment of tolerances for canola 
    seed at 1.75 ppm, and canola oil at 3.75 ppm.
        3. PP 8E5019 proposes the establishment of a tolerance for 
    cranberries at 1.0 ppm.
    
    [[Page 6355]]
    
        4. PP 8E5021 proposes the establishment of a tolerance for mint at 
    10.0 ppm.
        5, PP 8E5020 proposes the establishment of tolerances for turnips 
    tops at 9.0 ppm, and turnip roots at 0.25 ppm.
        EPA has determined that the petitions contain data or information 
    regarding the elements set forth in section 408(d)(2) of the FFDCA; 
    however, EPA has not fully evaluated the sufficiency of the submitted 
    data at this time or whether the data support granting of the 
    petitions. Additional data may be needed before EPA rules on the 
    petitions.
    
    A. Residue Chemistry
    
        1. Plant metabolism. The metabolism of tebufenozide in plants 
    (grapes, apples, rice, and sugar beets) is adequately understood for 
    the purpose of these tolerances. The metabolism of tebufenozide in all 
    crops was similar and involves oxidation of the alkyl substituents of 
    the aromatic rings primarily at the benzylic positions. The extent of 
    metabolism and degree of oxidation are a function of time from 
    application to harvest. In all crops, parent compound comprised the 
    majority of the total dosage. None of the metabolites were in excess of 
    10% of the total dosage.
        2. Analytical method. High performance liquid chromatographic 
    (HPLC) analytical methods using ultraviolet(UV) detection have been 
    validated for blueberries, raspberries, canola seed and oil, 
    cranberries, mint foliage and oil, and turnip roots and tops. The 
    methods involve extraction by blending with solvents, purification of 
    the extracts by liquid-liquid partitions and final purification of the 
    residues using solid phase extraction column chromatography. The limits 
    of quantitation (LOQ) is 0.005 ppm for blueberries, 0.01 ppm for canola 
    seed and meal, mint foliage, raspberries, and turnip roots and tops, 
    0.02 ppm for mint oil, 0.03 ppm for canola soapstock and oil, and 0.05 
    ppm for cranberries.
        3. Magnitude of residues. Field residue trials were conducted with 
    a 70 wettable power (WP) formulation in geographically representative 
    regions of the U.S. A total of 8 field residue trials were conducted in 
    blueberries. The average blueberry residue value from all trials was 
    0.81 ppm.
        A total of 7 field residue trials were conducted in canola. The 
    average canola seed residue value from all trials was 0.84 ppm. Two 
    processing studies were conducted. Average residues in meal, soapstock 
    and oil were 0.11 ppm, 0.83 ppm, and 1.75 ppm, respectively. Residues 
    did not concentrate in soapstock (Concentration Factor (CF) is less 
    than 1), and a tolerance in soapstock is not needed. For oil, the 
    average CF is 2.26, and the proposed tolerance is 3.75 ppm (2.26 times 
    1.58 ppm).
        A total of 6 field residue trials were conducted in cranberries. 
    The average cranberry residue value from all trials was 0.30 ppm.
        A total of 5 field residue trials were conducted in mint. The 
    average mint foliage residue value from all trials was 7.11 ppm. Mint 
    oil was prepared from foliage from two residue trials. The average oil 
    residue was 0.23 ppm. Since residues do not concentrate in oil, a 
    tolerance is not needed.
        A total of 5 field residue trials were conducted in raspberries. 
    The average raspberry residue value from all trials was 0.62 ppm.
        A total of 6 field residue trials were conducted in turnips. The 
    average residue value from all trials was 0.10 ppm for roots, and 2.27 
    ppm for tops.
    
    B. Toxicological Profile
    
        1. Acute toxicity. Results of a battery of toxicological studies 
    show tebufenozide has low acute toxicity. Tebufenozide Technical was 
    practically non-toxic by ingestion of a single oral dose in rats, and 
    mice (LD50 > 5,000 milligram/kilograms (mg/kg)) and was 
    practically non-toxic by dermal application LD50 > 5,000 mg/
    kg. Tebufenozide Technical was not significantly toxic to rats after a 
    4 hour inhalation exposure with an LC50 value of 4.5 
    mg/L (highest attainable concentration), is not considered 
    to be a primary eye irritant or a skin irritant, and is not a dermal 
    sensitizer. An acute neurotoxicity study in rats did not produce any 
    neurotoxic or neuropathologic effects.
        2. Genotoxicty. Tebufenozide technical was negative (non-mutagenic) 
    in an Ames assay with and without hepatic enzyme activation and in a 
    reverse mutation assay with E. coli. Tebufenozide technical was 
    negative in a hypoxanthine guanine phophoribosyl transferase (HGPRT) 
    gene mutation assay using Chinese hamster ovary (CHO) cells in culture 
    when tested with and without hepatic enzyme activation. In isolated rat 
    hepatocytes, tebufenozide technical did not induce unscheduled DNA 
    synthesis (UDS) or repair when tested up to the maximum soluble 
    concentration in culture medium. Tebufenozide did not produce 
    chromosome effects in vivo using rat bone marrow cells or in vitro 
    using Chinese hamster ovary cells (CHO). On the basis of the results 
    from this battery of tests, it is concluded that tebufenozide is not 
    mutagenic or genotoxic.
        3. Reproductive and developmental toxicity. See discussion of 
    studies under section E.2. Infant and Children.
        4. Subchronic toxicity-- i. The no-observed adverse effect level 
    (NOAEL) in a 90 day rat feeding study was 200 ppm (13 mg/kg/day for 
    males, 16 mg/kg/day for females). The lowest-observed adverse effect 
    level (LOAEL) was 2,000 ppm (133 mg/kg/day for males, 155 mg/kg/day for 
    females). Decreased body weight in males, and females was observed at 
    the LOAEL of 2,000 ppm. As part of this study, the potential for 
    tebufenozide to produce subchronic neurotoxicity was investigated. 
    Tebufenozide did not produce neurotoxic or neuropathologic effects when 
    administered in the diets of rats for 3 months at concentrations up to 
    and including the limit dose of 20,000 ppm (NOAEL = 1,330 mg/kg/day for 
    males, and 1,650 mg/kg/day for females).
        ii. In a 90 day feeding study with mice, the NOAEL was 20 ppm (3.4 
    and 4.0 mg/kg/day for males and females, respectively). The LOAEL was 
    200 ppm (35.3 and 44.7 mg/kg/day for males and females, respectively). 
    Decreases in body weight gain were noted in male mice at the LOAEL of 
    200 ppm.
        iii. A 90 day dog feeding study gave a NOAEL of 50 ppm (2.1 mg/kg/
    day for males and females). The LOAEL was 500 ppm (20.1 and 21.4 mg/kg/
    day for males and females, respectively). At the LOAEL, females 
    exhibited a decrease in rate of weight gain and males presented an 
    increased reticulocyte.
        iv. A 10 week study was conducted in the dog to examine the 
    reversibility of the effects on hematological parameters that were 
    observed in other dietary studies with the dog. Tebufenozide was 
    administered for 6 weeks in the diet to 4 male dogs at concentrations 
    of either 0 or 1,500 ppm. After the 6 weeks, the dogs receiving treated 
    feed were switched to the control diet for 4 weeks. Hematological 
    parameters were measured in both groups prior to treatment, at the end 
    of the 6 weeks treatment, after 2 weeks of recovery on the control diet 
    and after 4 weeks of recovery on the control diet. All hematological 
    parameters in the treated/recovery group were returned to control 
    levels indicating that the effects of tebufenozide on the hemopoietic 
    system are reversible in the dog.
        v. In a 28 day dermal toxicity study in the rat, the NOAEL was 
    1,000 mg/kg/day highest dose tested (HDT). Tebufenozide did not produce 
    toxicity in the rat when administered dermally
    
    [[Page 6356]]
    
    for 4 weeks at doses up to and including the limit dose of 1,000 mg/kg/
    day.
        5. Chronic toxicity-- i. A 1 year feeding study in dogs resulted in 
    decreased red blood cells, hematocrit, and hemoglobin and increased 
    Heinz bodies, reticulocytes, and platelets at the LOAEL of 8.7 mg/kg/
    day. The NOAEL in this study was 1.8 mg/kg/day.
        ii. An 18 month mouse carcinogenicity study showed no signs of 
    carcinogenicity at dosage levels up to and including 1,000 ppm, the 
    HDT.
        iii. In a combined rat chronic/oncogenicity study, the NOAEL for 
    chronic toxicity was 100 ppm (4.8 and 6.1 mg/kg/day for males and 
    females, respectively), and the LOAEL was 1,000 ppm (48 and 61 mg/kg/
    day for males and females, respectively). No carcinogenicity was 
    observed at the dosage levels up to 2,000 ppm (97 mg/kg/day and 125 mg/
    kg/day for males and females, respectively).
        6. Animal metabolism. The adsorption, distribution, excretion and 
    metabolism of tebufenozide in rats was investigated. Tebufenozide is 
    partially absorbed, is rapidly excreted and does not accumulate in 
    tissues. Although tebufenozide is mainly excreted unchanged, a number 
    of polar metabolites were identified. These metabolites are products of 
    oxidation of the benzylic ethyl or methyl side chains of the molecule. 
    These metabolites were detected in plant and other animal (rat, goat, 
    and hen) metabolism studies.
        7. Metabolite toxicology. Common metabolic pathways for 
    tebufenozide have been identified in both plants (grape, apple, rice, 
    and sugar beet), and animals (rat, goat, and hen). The metabolic 
    pathway common to both plants and animals involves oxidation of the 
    alkyl substituents (ethyl and methyl groups) of thearomatic rings 
    primarily at the benzylic positions. Extensive degradation and 
    elimination of polar metabolites occurs in animals such that residues 
    are unlikely to accumulate in humans or animals exposed to these 
    residues through the diet.
    
    C. Aggregate Exposure
    
        1. Dietary exposure--i. Food. Tolerances have been established (40 
    CFR 180.482) for the residues of tebufenozide, in or on a variety of 
    raw agricultural commodities. A permanent tolerance has been 
    established for the residues of tebufenozide in/on walnuts at 0.1 ppm, 
    and pecans at 0.05 ppm. Permanent tolerances at 0.5 ppm and 1.0 ppm 
    have been established for imported wine grapes, and apples, 
    respectively. Other proposed tolerances are pending. Risk assessments 
    were conducted by Rohm and Haas to assess dietary exposures and risks 
    from tebufenozide as follows:
        ii. Acute exposure and risk. No acute endpoint was identified for 
    tebufenozide and no acute risk assessment is required.
        iii. Chronic exposure and risk. For chronic dietary risk 
    assessment, it is assumed that 100% of all crops which are consumed 
    will contain residues of tebufenozide at the tolerance levels. The 
    Reference Dose (RfD) used for the chronic dietary analysis is 0.018 mg/
    kg/day. Potential chronic exposures were estimated using NOVIGEN'S 
    Dietary Exposure Evaluation Model (DDEM Version 5.03b) which uses USDA 
    food consumption data from the 1989-1992 survey. The existing and 
    proposed tebufenozide tolerances result in a theoretical maximum 
    residue contribution (TMRC) that is equivalent to 34.5% of the RfD for 
    the U.S. population, 61.4% of the RfD for infants, 70.4% of the RfD for 
    non-nursing infants (> 1 year old), and 79.8% of the RfD for chlidren 1 
    to 6 years old. The chronic dietary risks from these uses do not exceed 
    EPA's level of concern.
        iv. Drinking water. Submitted environmental fate studies suggest 
    that tebufenozide is moderately persistent to persistent and mobile, 
    and could potentially leach to groundwater and runoff to surface water 
    under certain environmental conditions. However, in terrestrial field 
    dissipation studies, residues of tebufenozide and its soil metabolites 
    showed no downward mobility and remained associated with the upper 
    layers of soil. Foliar interception (up to 60% of the total dosage 
    applied) by target crops reduces the ground level residues of 
    tebufenozide. There is no established Maximum Concentration Level (MCL) 
    for residues of tebufenozide in drinking water. No drinking water 
    health advisory levels have been established for tebufenozide. There is 
    no entry for tebufenozide in the ``Pesticides in Groundwater Database'' 
    (EPA 734-12-92-001, September 1992).
        v. Chronic exposure and risk. There are insufficient water-related 
    exposure data to complete a comprehensive drinking water assessment for 
    tebufenozide at this time. However, in order to mitigate the potential 
    for tebufenozide to leach into groundwater or runoff to surface water, 
    precautionary language has been incorporated into the product label. 
    Considering the precautionary language on the label and based on the 
    Registrant's knowledge of environmental occurrence of the chemicals, 
    significant exposure from residues of tebufenozide in drinking water is 
    not anticipated.
        2. Non-dietary exposure. Tebufenozide is not currently registered 
    for any indoor or outdoor residential uses; therefore, no non-dietary 
    residential exposure is anticipated.
    
    D. Cumulative Effects
    
        The potential for cumulative effects of tebufenozide with other 
    substances that have a common mechanism of toxicity was considered. 
    Tebufenozide belongs to the class of insecticide chemicals known as 
    diacylhydrazines. The only other diacylhydrazine currently registered 
    for non-food crop uses is halofenozide. Tebufenozide and halofenozide 
    both produce a mild, reversible anemia following subchronic/chronic 
    exposure at high doses; however, halofenozide also exhibits other 
    patterns of toxicity (liver toxicity following subchronic exposure and 
    developmental/systemic toxicity following acute exposure) which 
    tebufenozide does not. Given the different spectrum of toxicity 
    produced by tebufenozide, Rohm Haus concludes that there is no reliable 
    data at the molecular/mechanistic level which would indicate that toxic 
    effects produced by tebufenozide would be cumulative with those of 
    halofenozide (or any other chemical compound).
        Based on the overall pattern of toxicity produced by tebufenozide 
    in mammalian and insect systems, the compound's toxicity appears to be 
    distinct from that of other chemicals, including organochlorines, 
    organophosphates, carbamates, pyrethroids, benzoylureas, and other 
    diacylhydrazines. Thus, according to Rohm Haus, there is no evidence to 
    date to suggest that cumulative effects of tebufenozide and other 
    chemicals should be considered.
    
    E. Safety Determination
    
        1. U.S. population-- i. Acute exposure and risk. Since no acute 
    endpoint was identified for tebufenozide, no acute risk assessment is 
    required.
        ii. Chronic exposure and risk. Using the conservative exposure 
    assumptions described above and taking into account the completeness 
    and reliability of the toxicity data, the percentage of the RfD that 
    will be utilized by dietary (food only) exposure to residues of 
    tebufenozide from existing, pending and proposed tolerances is 34.5% 
    for the U.S. population. Aggregate exposure (food and water) are not 
    expected to exceed 100%. EPA generally has no concern for exposures 
    below 100% of
    
    [[Page 6357]]
    
    the RfD because the RfD represents the level at or below which daily 
    aggregate dietary exposure over a lifetime will not pose appreciable 
    risks to human health. Rohm and Haas concludes that there is a 
    reasonable certainty that no harm will result from aggregate exposure 
    to tebufenozide residues to the U.S. population.
        2. Infants and children-children-- i. In general. In assessing the 
    potential for additional sensitivity of infants and children to 
    residues of tebufenozide, data from developmental toxicity studies in 
    the rat and rabbit, and 2-generation reproduction studies in the rat 
    are considered. The developmental toxicity studies are designed to 
    evaluate adverse effects on the developing organism resulting from 
    maternal pesticide exposure during gestation. Reproduction studies 
    provide information relating to effects from exposure to the pesticide 
    on the reproductive capability of mating animals and data on systemic 
    toxicity.
        ii. Developmental toxicity studies-- a.  Rats. In a developmental 
    toxicity study in rats, the maternal (systemic) NOAEL was 250 mg/kg/
    day. The LOAEL was 1,000 mg/kg/day based on decrease body weight and 
    food consumption. The developmental (pup) NOAEL as > 1,000 mg/kg/day 
    HDT.
        b. Rabbits. In a developmental toxicity study in rabbits, the 
    maternal and developmental NOAELs were > 1,000 mg/kg/day HDT.
        iii. Reproductive toxicity study rats. In a multigeneration 
    reproductive toxicity study in rats, the parental (systemic) NOAEL was 
    0.85 mg/kg/day. Spleenic pigmentation changes and extramedullary 
    hematopoiesis occurred at the LOAEL of 12.1 mg/kg/day. In addition to 
    these effects, decreased body weight gain and food consumption occurred 
    at 171.1 mg/kg/day. The reproductive (pup) NOAEL was 12.1 mg/kg/day. 
    The reproductive LOAEL of 171.1 mg/kg/day was based on a slight 
    increase in the number of pregnant females that did not deliver or had 
    difficulty and had to be sacrificed. Additionally at the LOAEL, in F1 
    dams, the length of gestation increased and implantation sites 
    decreased significantly. In a second study, reproductive effects were 
    not observed at 2,000 ppm (the NOAEL equal to 149-195 mg/kg/day) and 
    the NOAEL for systemic toxicity was determined to be 25 ppm (1.9-2.3 
    mg/kg/day).
        iv. Pre- and post-natal sensitivity-- a. Pre-natal sensitivity. The 
    developmental NOAELs of > 1,000 mg/kg/day HDT from the developmental 
    toxicity studies in rats and rabbits demonstrate that there is no 
    developmental (prenatal) toxicity present for tebufenozide.
        Additionally, these developmental NOAELs are greater than 500-fold 
    higher than the NOAEL of 1.8 mg/kg/day from the 1 year feeding study in 
    dogs which was the basis of the RfD.
        b. Post-natal sensitivity. In the reproductive toxicity study in 
    rats, the reproductive NOAEL (12.1 mg/kg/day from the first study; 149-
    195 mg/kg/day from the second study) is between 14-fold higher than the 
    parental NOAEL (0.85 mg/kg/day) in the first study and 83-fold higher 
    than the parental NOAEL (1.8-2.3 mg/kg/day) in the second study. These 
    data indicate that post-natal toxicity in the reproductive studies 
    occurs only in the presence of significant parental toxicity. These 
    developmental and reproductive studies indicate that tebufenozide does 
    not have additional post-natal sensitivity for infants and children in 
    comparison to other exposed groups. Because these reproductive effects 
    occurred in the presence of parental (systemic) toxicity and were not 
    replicated at the same doses in a second study, these data do not 
    indicate an increased pre-natalor post-natal sensitivity to children 
    and infants (that infants and children might be more sensitive than 
    adults) to tebufenozide exposure.
        c. Acute exposure and risk. Since no acute endpoint was identified 
    for tebufenozide, no acute risk assessment is required.
        d. Chronic exposure and risk. With the existing, pending and 
    proposed tolerances for tebufenozide, the percentage of the RfD that 
    will be utilized by dietary (food only) exposure to residues of 
    tebufenozide range from 39.9% for nursing infants less than 1 year old 
    to 79.8.% for children 1 to 6 years old. Aggregate exposure (food and 
    water) are not expected to exceed 100%. Rohm and Haas concludes that 
    there is a reasonable certainty that no harm will result from aggregate 
    exposure to tebufenozide residues to non-nursing infants.
    
    F. International Tolerances
    
        There are currently no CODEX, Canadian or Mexican maximum residue 
    levels (MRLs) established for tebufenozide in blueberries, caneberries, 
    canola, cranberries, mint or turnips so no harmonization issues are 
    required for this action.
    [FR Doc. 99-3146 Filed 2-8-99; 8:45 am]
    BILLING CODE 6560-50-F
    
    
    

Document Information

Published:
02/09/1999
Department:
Environmental Protection Agency
Entry Type:
Notice
Action:
Notice.
Document Number:
99-3146
Dates:
Comments, identified by the docket control number PF-856, must be received on or before March 11, 1999.
Pages:
6351-6357 (7 pages)
Docket Numbers:
PF-856, FRL-6058-3
PDF File:
99-3146.pdf